Induction chemotherapy with paclitaxel, carboplatin, and cetuximab (PCE) followed by chemoradiotherapy for unresectable locoregional recurrence after curative surgery in patients with squamous cell carcinoma of the head and neck.

3.3 Prognosis With a median follow-up time of 31.2 months (range: 5.5 – 88.6) in the total population, the IC-PCE group showed a trend toward better PFS and OS than the CRT group (2-year PFS: 55.6% vs. 33.3%, log-rank p =0.176, 2-year OS: 92.6% vs. 79.0%, log-rank p =0.541) ( Figures 2A, B ).

also in 53,322 other papers